ArrowMark Colorado Holdings’s Pacific Biosciences PACB Stock Holding History

ArrowMark Colorado Holdings’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$787K	Hold	468,382	–	–	0.03%	257
2026 Q1	$618K	Hold	468,382	–	–	0.02%	260
2025 Q4	$876K	Hold	468,382	–	–	0.02%	265
2025 Q3	$600K	Hold	468,382	–	–	0.01%	270
2025 Q2	$581K	Hold	468,382	–	–	0.01%	268
2025 Q1	$553K	Hold	468,382	–	–	0.01%	269
2024 Q4	$857K	Hold	468,382	–	–	0.01%	265
2024 Q3	$796K	Hold	468,382	–	–	0.01%	256
2024 Q2	$642K	Hold	468,382	–	–	0.01%	279
2024 Q1	$1.76M	Buy	468,382 +235,196	+101%	+$1.38M	0.02%	247
2023 Q4	$2.29M	Hold	233,186	–	–	0.03%	235
2023 Q3	$1.95M	Buy	+233,186	New	+$2.66M	0.02%	234
2020 Q2	–	Sell	-2,816,791	Closed	-$8.62M	–	319
2020 Q1	$8.62M	Sell	2,816,791 -920,271	-25%	-$3.77M	0.11%	148
2019 Q4	$19.2M	Buy	3,737,062 +273,897	+8%	+$1.39M	0.17%	114
2019 Q3	$17.9M	Buy	3,463,165 +58,301	+2%	+$326K	0.18%	108
2019 Q2	$20.6M	Buy	3,404,864 +21,580	+0.6%	+$151K	0.2%	107
2019 Q1	$24.5M	Sell	3,383,284 -79,008	-2%	-$571K	0.23%	100
2018 Q4	$25.6M	Sell	3,462,292 -297,194	-8%	-$1.88M	0.27%	102
2018 Q3	$20.3M	Sell	3,759,486 -748,308	-17%	-$3.21M	0.17%	119
2018 Q2	$16M	Sell	4,507,794 -258,618	-5%	-$717K	0.15%	141
2018 Q1	$9.77M	Buy	4,766,412 +868,102	+22%	+$2.25M	0.1%	183
2017 Q4	$10.3M	Buy	3,898,310 +795,699	+26%	+$2.79M	0.1%	184
2017 Q3	$16.3M	Sell	3,102,611 -331,776	-10%	-$1.43M	0.19%	118
2017 Q2	$12.2M	Buy	3,434,387 +1,153,374	+51%	+$4.65M	0.15%	135
2017 Q1	$11.8M	Buy	2,281,013 +809,459	+55%	+$3.96M	0.16%	121
2016 Q4	$5.59M	Buy	1,471,554 +536,594	+57%	+$3.9M	0.09%	174
2016 Q3	$8.38M	Buy	934,960 +607,552	+186%	+$5.08M	0.15%	129
2016 Q2	$2.3M	Buy	327,408 +104,486	+47%	+$955K	0.05%	194
2016 Q1	$1.9M	Buy	222,922 +55,964	+34%	+$550K	0.04%	186
2015 Q4	$2.19M	Buy	+166,958	New	+$1.5M	0.06%	185

Other funds holding PACB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ArrowMark Colorado Holdings's PACB Position: Q2 2026 in Review

ArrowMark Colorado Holdings held its Pacific Biosciences (PACB) position steady in Q2 2026 at 468,382 shares worth $787K. The position accounts for 0.03% of the portfolio, ranked #257.

ArrowMark Colorado Holdings first reported a position in PACB in Q4 2015 and has held it in 30 quarters since. The position peaked at $25.6M in Q4 2018. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

ArrowMark Colorado Holdings held 468,382 shares of Pacific Biosciences worth $787K as of Q2 2026.
ArrowMark Colorado Holdings left its Pacific Biosciences share count unchanged in Q2 2026.
Pacific Biosciences made up 0.03% of ArrowMark Colorado Holdings's portfolio in Q2 2026, its #257 holding.
ArrowMark Colorado Holdings first reported a position in Pacific Biosciences in Q4 2015 and has held it in 30 quarters since.
ArrowMark Colorado Holdings's Pacific Biosciences position peaked at $25.6M in Q4 2018.
223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on ArrowMark Colorado Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.